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ABSTRACT
Background. Papillary or follicular thyroid carcinomas
exhibit a relatively benign course. Hence, long-term
follow-up studies with well-defined disease stages and
treatment details are needed to evaluate treatment
strategies.
Methods. Patients who underwent complete resection of
well-differentiated thyroid carcinoma (WDTC) confined to
the thyroid gland between 1972 and 1990 identified from a
prospective database were assessed. Follow-up was per-
formed by interview, review of patient charts, and analysis
of the Death Registry. Primary endpoints were overall
survival (OS) and disease-specific survival (DSS). Review
of histology was performed and extent of thyroid resection,
postoperative therapy, and recognized prognostic factors
but not lymphadenectomy were evaluated.
Results. Of 2,867 patients, 213 had complete resection of
WDTC confined to the thyroid gland. Follow-up was
completed in 166 patients with median age 54.2 (range,
20–85) years, and median follow-up of 27.2 (range, 15.6–
34.5) years. The 10- and 20-year OS was 71 and 55%,
respectively. DSS at 10 and 20 years was 81 and 69%,
respectively, and correlated with age, histology, tumor size,
radio-iodide ablation (RIA), and external beam irradiation
(EBR) treatment. No patient died of WDTC more than
18 years after resection. Total or near-total thyroidectomy
without lymphadenectomy was not superior to partial
thyroidectomy. In multivariate analysis for DSS, age was
the dominant factor, which correlated with histology.
Conclusion. After a median follow-up of 27 years, about
one-third of patients died of WDTC. Age, histology and
postoperative therapy but not extent of thyroid resection
determined DSS.
Thyroid cancer accounts for roughly 0.5–1.5% of all
cancers. Although it is a rare cancer, it is the most common
endocrine malignancy.1 More than 94% of malignant thy-
roid tumors arise from follicular epithelial cells to form
well-differentiated papillary or follicular carcinomas
(WDTC) (reviewed in Sherman2). Most WDTC display a
relatively benign disease course with a reported 10-year
disease-specific survival (DSS) of up to 96% for papillary
thyroid carcinoma (PTC) and 90% for follicular thyroid
carcinoma (FTC).3,4
The low tumorigenicity of this cancer renders the deter-
mination of optimal treatment strategies through prospective
clinical trials with meaningful follow-up periods nearly
impossible. Therefore, an evaluation of factors that influence
overall survival (OS) and DSS is dependent on retrospective
studies based either on large study populations or on long-
term follow-up. Both approaches have inherent limitations.
Most large observational studies with median follow-up of
10 and more years are based on databases from cancer reg-
istries not specific for thyroid tumors. These are limited by
the lack of detailed descriptions of tumor characteristics and/
or exact treatments applied.4,5 On the other hand, and with
the exception of the studies from the Mayo Clinics, long-
term follow-up studies from well-defined study groups that
are typically derived from single-institutional thyroid-spe-
cific prospective databases are hampered by small sample
sizes and treatment inconsistencies that occur during the long
time over which patients were included.6,7
Various clinicopathological prognostic factors have
been integrated in more than 15 different tumor staging
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systems for WDTC.8 Most systems are based on the risk
factors age, tumor size, and presence of metastatic disease
used to stratify patients in risk groups for disease-specific
survival (DSS). The MACIS-, EORTC-, and AJCC/UICC
TNM staging systems reportedly have the best predictive
accuracy (AJCC/UICC 6th edition).9 Of these staging
instruments, only the MACIS system integrates complete-
ness of resection.10 Additional factors associated with
disease recurrence but not necessarily DSS were the pres-
ence of extrathyroidal spread, regional lymph node
metastases, and postoperative radio-iodine ablation therapy
(RIA).11–14
As for most solid tumors, surgical resection is the
mainstay of treatment. Whereas the importance of com-
plete tumor resection is acknowledged, the extent of
additional thyroid tissue that must be removed and the
implementation of lymphadenectomy remain controversial.
Proponents of total thyroidectomy justify this approach
because of the high rate of multifocality with bilateral
disease in PTC. In addition, total thyroidectomy facilitates
the detection of postoperative recurrence and metastasis by
radioiodine uptake and thyroglobulin serum level mea-
surements. Indeed, many investigators found that more
extensive resection of DTC with total or near-total thy-
roidectomy results in a lower incidence of local
recurrences, although it does not influence DSS.15–21
Recently, Bilimoira et al.22 showed a survival benefit after
total thyroidectomy over lobectomy in PTC larger than
1 cm analyzing a cancer registry database. Proponents of
limited resection base their strategy on publications
reporting that postsurgical complications increased with
more extensive resection. Data about DSS in these studies
seem to justify limited thyroid resection, favoring lobec-
tomy of the affected side over total thyroidectomy.7,14,23–32
In this retrospective study of a well-defined patient
group with WDTC confined to the thyroid gland under-
going complete resection of the tumor, we sought to define
long-term outcomes, to evaluate previously described
prognostic factors for DSS in WDTC, and to determine the
influence of the extent of thyroid resection, in particular.
PATIENTS AND METHODS
Since 1972, clinical and pathologic data, treatment
rendered, intraoperative findings, and follow-up informa-
tion for all patients undergoing thyroid surgery at the
Department of Visceral and Transplantation Surgery,
University Hospital of Bern, have been entered in a com-
prehensive databank. From the group of patients with
WDTC, papillary (PTC), or follicular (FTC) carcinomas
who were surgically treated between 1972 and 1990, we
identified patients who had complete resection of primary
tumors confined to the thyroid gland, with no macroscopic
spread to adjacent lymph nodes. To avoid misinterpretation
for inconsistencies in lymph node surgery, patients who
had enlarged lymph nodes and, hence, lymphadenectomy
were excluded. Patients who died within 30 days of initial
thyroid resection were excluded. Distant metastasis was
determined by whole body scan at the beginning of RIA
treatment, and positive patients were excluded. Histology
was confirmed or restaged by an actual review of tumor
blocks at the Pathology Institute of the University of Bern.
These patients formed the study population.
The following definitions were used. The time of diag-
nosis was defined as the date of initial resection. Tumor
size was defined as the maximum dimension of the resected
tumor described in the pathologic report. The maximal size
of a T1 tumor was 2 cm, of a T2 tumor was [2 to B4 cm,
and of a T3 tumor was [4 cm, with the entire tumor lim-
ited to the thyroid. The TNM tumor stage was determined
according to the UICC AJCC TNM classification of
malignant tumors33: In the absence of distant metastasis,
age \45 years or tumor size T1 in older patients defines
Stage I. Tumor size T2 in patients older than 45 years is
classified as Stage II; Stage III correlates to a T3 tumor or
any lymph node involvement in patients [45 years. For
PTC, the staging system from the Mayo clinic based on
metastasis, age, completeness of resection, invasion, and
tumor size (MACIS), was also used.10 The definition of
complete surgical excision was based on information from
the surgical and histopathologic reports indicating com-
plete removal of the entire primary tumor. The extent of
resection was defined as total thyroid resection (TR) if less
than 1 g (near-total) of thyroid tissue was left behind
(partial resection (PR) if more than 1 g was left in place).
Postoperative radio-iodide ablation consisted of post-
operative application of 30–200 mCi 131I, and a post-
therapy scan was routinely performed. External beam
irradiation (EBR) consisted of a postoperative application
of 30 Gy, typically.
A retrospective analysis of the data, including a review
of patient charts, was performed in 2007. The follow-up
was achieved by telephone-interview, review of patient
charts from family practitioners, and analysis of the Swiss
Death Registry for cause of death in nonsurvivors. Primary
endpoints were overall survival (OS) and DSS. Due to the
long follow-up period, disease-free survival could not be
reliably determined.
For statistical analysis, associations among categorical
variables were tested using the chi-square or Fisher exact
test, where appropriate. The OS and DSS were defined as
the time from initial resection to the date of death from any
cause (OS), or death from disease (DSS). Patients who did
not die were censored for OS or DSS analysis at the time of
last follow-up. The OS and DSS curves were generated
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using the Kaplan–Meier method.34 The log-rank test was
used to test for differences among patient groups. Inde-
pendent prognostic factors were examined using the Cox
proportional hazards regression model.35 Statistical analy-
ses were performed using NCSS software (NCSS and
PASS. Number Cruncher Statistical Systems. and Power
Analysis Statistical Software; Kaysville, UT). A P value
of \ .05 was considered significant.
RESULTS
A total of 213 Swiss patients with primary WDTC were
treated at the University Hospital of Bern during the study
period (1972–1990). Of these, 186 had tumors confined to
the thyroid (no extension beyond the thyroid capsule) that
were resected with tumor-free margins. Patients who had
lymphadenectomy caused by enlarged lymph nodes were
excluded. This led to a highly selected group of 186
patients with macroscopically localized disease and
microscopically confirmed complete resection of the
carcinoma (Table 1). A review of histology led to the
exclusion of 5 patients (4 adenomas, 1 anaplastic carci-
noma) and restaging of 14 initial FTCs to PTC. Follow-up
was complete in 166 of the 181 patients. The median fol-
low-up time was 27.2 years (range, 15.6–34.3). The
distribution of clinicopathologic factors in all 166 patients
with complete resection of localized WDTC is summarized
in Table 1. The median age of the study population at
TABLE 1 Characteristics and treatment of 166 patients with well-differentiated thyroid cancer
Characteristics No. of patients
All
Thyroid surgery 2867
Primary well-differentiated thyroid carcinoma 213
Localized disease ? resection margin free 186
Total PTC FTC
Questionnaire and follow-up completed
Before revision
181 69 (42%) 102 (56%)
Huertle 15 (9%)
Histologic revision 166 83 (50%) 83 (50%) (including
Huertle, n = 15 [9%])
Median f/u (range), years 27.2 (15.8–34.3) 26.3 (15.8–34.3) 29.8 (16.7–33.9)
Median age (range), years 54.2 (20.2–85) 42.2 (20.2–83.2) 63.5 (20.2–85)
Age \ 60 years 95 (57%) 61 (64%) 34 (36%)
Men/women 51/115 27/56 24/59
Tumor size T (UICC TNM 6th ed.)
T1 (\2 cm); [pT1a (\1 cm)] 42 (50%); [26 (50%)] 8 (9%); [0]
T2 18 (22%) 13 (16%)
T3 ([4 cm) 23 (28%) 62 (75%)
n (%) n (%) n (%)
Surgical procedure
Total or near-total thyroid resection (TR) 63 (38) 30 (37) 33 (40)
Partial thyroid resection (PR) 103 (62) 53 (64) 50 (60)
Subtotal unilateral thyroid resection 8 (5) 6 (7) 2 (2)
Bilateral incomplete lobectomy 8 (5) 7 (8) 1 (1)
Hemithyroidectomy (lobectomy) 32 (19) 14 (17) 18 (21)
Subtotal thyroidectomy 55 (33) 26 (31) 29 (35)
Ipsilateral partial lymphadenectomy 25 (15) 15 (18) 10 (12)
Postoperative treatment
131I radio-iodine (RIA) 106 (64) 52 (63) 54 (65)
EBR 11 (7) 2 (3) 9 (11)
RIA ? EBR 23 (14) 11 (13) 12 (15)
f/u follow-up, PTC papillary thyroid carcinoma, FTC follicular thyroid carcinoma, EBR external beam radiation, Huertle Huertle cell carcinoma
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diagnosis was 54.2 years (range 20.2–86). The number of
women was more than double that of men (115 vs. 51). Of
patients with PTC, 50% presented with T1 tumors
(tumor \ 2 cm), 23% with T2 tumors ([2 cm and B4 cm),
and 27% with T3 tumors ([4 cm but limited to the thy-
roid). Because 49 patients (59%) with PTC were \45 years
of age, 73% (n = 61) of all PTC were considered UICC
stage I (\45 years or [45 years and T1N0M0). For
patients with FTC, the percentages with T1, T2, and T3
tumors were 9, 16, and 75%, respectively. Thirteen (16%)
patients with FTC had UICC stage I (\45 years: n = 12).
However, because lymphadenectomy was only sporadi-
cally performed (PTC 18% and FTC 12%), one cannot
exclude the possibility of understaging in UICC stages I
and II because of missed positive lymph nodes in patients
older than 45 years with tumor sizes T1 or T2 (PTC,
n = 6; FTC, n = 11). For the 6 patients with PTC we used
a sensitivity analysis; by assuming stage III disease (posi-
tive lymph nodes) no influence on prognostic factors was
detected.
Treatment of Well-Differentiated Thyroid Carcinoma
Total or near-total thyroidectomy (TR) was the surgical
procedure of choice in about one-third (38%) of the
patients (PTC, 37%; FTC, 40%) (Table 1). If no total or
near-total resection of the thyroid was performed, subtotal
thyroidectomy was the most common alternative surgical
procedure. Less frequently, hemithyroidectomy (lobec-
tomy) was performed (19%). Unilateral or bilateral subtotal
thyroid resection (unilateral or bilateral incomplete lobec-
tomy) were rarely performed (5% each). During the period
of interest (1972–1990), extensive (cervico-central and
cervico-lateral) lymphadenectomy was only performed in
cases highly suspicious of lymph node involvement and
was not routinely performed at the University Hospital of
Bern. In our cohort, we excluded patients with macroscopic
lymph node involvement to avoid the bias of additional
extensive lymphadenectomy. Limited lymphadenectomy
on the ipsilateral side, removal of a few isolated lymph
nodes (berry picking) was reported in 25 patients (15%):
n = 15 in PTC (T2: n = 9, T3: n = 6); n = 10 in FTC
(T2: n = 2, T3: n = 8).
Postoperative treatment consisted of either 131I RIA
(64%) or external-beam radiation therapy (EBR) (7%) or a
combination of both radiotherapies (14%). There were 18
PTC patients and 8 FTC patients who did not receive
postoperative treatment (Table 1).
Overall Survival
A total of 75 patients survived the observation period
(45%). The median OS for all patients was 21.7 years (95%
confidence interval [95% CI], 17.1–28) (Fig. 1a and
Table 2). The 10- and 20-year OS rates for the patients
after complete resection of WDTC were 71 and 55%. The
median OS for FTC was 14.2 years, whereas 68% of
patients with PTC (95%CI, 58–79) survived the observa-
tion period (median not reached).
Patients younger than 45 years at the time of resection
showed a 97% (95% CI, 92–100) and 93% (95% CI, 86–
100) 10 and 20 year OS, respectively. The survival rate
after 10 and 20 years in patients aged 45–60 years was
79% (95%CI, 66–93) and 46% (95% CI, 34–57), respec-
tively, and for patients older than 60 years of age was 58%
(95% CI, 41–75) and 20% (95% CI, 11–30), respectively
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FIG. 1 Kaplan–Meier curves for survival estimates with the number
of patients at risk. a Overall survival for patients with complete
resection of localized well-differentiated thyroid carcinoma. Median
OS was 21.7 (17.1–28.0) years and 20-year survival was 54.9% (47–
63%). b Disease-specific survival (DSS) for patients with complete
resection of localized well-differentiated thyroid carcinoma. At time
of last follow-up, 7 patients were alive with the disease. DSS 20-year
survival was 69% (62–77%). The median time to death from disease
was 6.7 (0.64–17.4) years
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Significant factors associated with worse OS in univar-
iate analysis were older age (hazard ratio [HR] 6.7 for
age [ 60 years); male gender (HR 2.1), histology of FTC
(HR 2.5), tumor size [ 4 cm (UICC T3) (HR 3.4), no
postoperative treatment with 131I- RIA (HR 2.3), and
treatment with EBR (HR 2.3) (Table 3).
In a multivariate analysis of OS that included age (\60
vs. [60 years), gender, tumor size (T \ 3 vs. T3), histol-
ogy (PTC vs. FTC), extent of resection (TR vs. PR),
postoperative RIA, and postoperative EBR, age was the
dominant risk factor (risk ratio = 0.09, 95%CI, 0.04–0.20,
P \ .001). The only other statistically significant factor for
OS was female gender (risk ratio = 0.53, 95%CI, 0.30–
0.95, P = .007).
Disease-Specific Survival
During the observation period, 51 (30.7%) patients died
of WDTC (Fig. 1b). At the time of follow-up, 7 patients
where alive with their disease. The DSS for PTC and FTC
after 20 years was 83 and 54%, respectively (Table 2).
The Kaplan–Meier estimates for DSS stratified by age
(P \ .001), histology (P \ .001), and tumor size
(P = .001) are shown in Fig. 2a–c. The DSS estimates
according to treatment option, extent of resection (P = not
significant [NS]), postoperative RIA therapy (P = .047),
and EBR (P = 0.002) are given in Fig. 3a–c. Univariate
analysis showed that patients older than 60 years had 9.2
times higher risk of dying of WDTC than younger patients
with this disease (HR 9.17) (Table 3). Other factors that
significantly increased the risk of death from WDTC were
FTC histology (HR 3.22), tumor size [4 cm (HR 4.16), not
receiving postoperative RIA therapy (HR 1.92), and
receiving EBR (HR 2.69) (Table 3).
In a subgroup analysis of patients with PTC,
age [60 years (P \ .001), tumor size [4 cm (P = .008),
and receiving EBR therapy (P = .001) were significant
factors predicting worse DSS (Table 4). The subgroup
analysis for DSS in patients with FTC showed age [60 -
years (P \ .001), postoperative RIA therapy (P = .013),
and Huertle cell differentiation (P = .047) to be significant
factors, whereas tumor size and treatment with EBR lost its
statistical significance (Table 4).
In a multivariate analysis of DSS that included age,
gender, histology, tumor size (T [ 4 cm), histology (PTC
vs. FTC), extent of resection, postoperative RIA treatment,
and postoperative EBR, age [60 years was the dominant
factor (risk ratio [RR] 4.91, 95%CI 0.029–0.25, P = .005)
with histology being the only other statistically significant
factor (RR 2.89 for FTC, P = .03).
In patients with PTC, the multivariate analysis of
significant factors from the univariate analysis (age,
tumor size, and receiving EBR), age again significantlyT
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influenced DSS (P \ .001). Age also remained the domi-
nant factor in multivariate analysis of patients with FTC. In
this subgroup, Huertle cell differentiation was dominated
by age (P = .09). The low power of these subgroups
(n = 83), however, limits the assessment of independent
prognostic factors by this multivariate analysis.
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FIG. 2 Kaplan–Meier curves for
estimates of disease-specific
survival (DSS) for patients
stratified by age (a); histology
(b); and tumor size (c). a DSS
differed significantly between age
groups: patients younger than
45 years (\45 years), between 45
and 60 years (45–60 years), and
older than 60 years ([60 years)
(P \ .001). b Patients with
papillary thyroid carcinoma
(PTC) had significantly better
DSS than patients with follicular
thyroid carcinoma (FTC)
stratified into FTC and Huertle
cell carcinoma (FTC and Huertle)
(P \ .001; log-rank). c DSS
stratified by TNM T-stage (tumor
size: T1–T3) were significantly
different (P \ .001; log-rank).
Numbers below the graphs show
patients at risk at the given time
points
TABLE 3 Univariate analysis for overall survival and disease-specific survival in 166 patients with resected well-differentiated thyroid cancer
Characteristics Disease-specific survival Overall survival
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Age, \ 60 vs. C 60 years 0.11 0.06–0.22 \.001* 0.15 0.09–0.25 \.001*
Gender, male vs. female 1.57 0.79–3.14 .16 2.09 1.20–3.42 \.001*
Histology, PTC vs. FTC
(without Huertle cell ca)
0.31 (0.36) 0.17–0.58 (0.18–0.73) \.001* (.003*) 0.40 (0.45) 0.26–0.62 (0.28–0.72) \.001* (.003*)
Tumor size, T1, 2 vs. [ T2
(\4 vs. C 4 cm)
0.24 0.12–0.47 .002* 0.29 0.17–0.50 \.001*
Radio-iodide therapy, yes vs. no 0.52 0.27–0.99 .047* 0.43 0.25–0.77 \.001*
EBR, yes vs. no 2.69 1.13–6.37 .002* 2.34 1.29–4.24 \.001*
Resection, PR vs. TR 1.40 0.75–2.63 .30 1.37 0.88–2.10 .17
PTC papillary thyroid carcinoma, FTC follicular thyroid carcinoma, EBR external beam radiation, PR partial thyroid resection, TR total or near-
total thyroid resection
HR was calculated with Cox-Mantel, P values calculated with log-rank test
* Statistically significant differences between groups (P \ .05)
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Extent of Resection
WDTC was most often removed by partial resection of the
thyroid gland (PR). Subtotal unilateral or bilateral thyroid
resection (10%) or hemithyroidectomy (lobectomy) (19%)
had the goal of complete resection of the cancer alone,
avoiding potential morbidity of more extensive resection.
The scope of subtotal thyroidectomy was primarily the
removal of the tumor with as much thyroid tissue as possible
to minimize the risk of unapparent synchronous carcinoma
and to allow effective postoperative RIA therapy (subtotal
thyroidectomy, 33%) (Table 1). Total or near-total (less than
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FIG. 3 Kaplan–Meier curves for
disease-specific survival (DSS)
estimates stratified by extent of
thyroid resection (a), by
application of postoperative radio-
iodide treatment (b), and by
treatment with postoperative
external beam radiation (EBR)
(c). a DSS did not differ
significantly between patients
treated with total/near-total
thyroidectomy (total resection,
TR) and with partial
thyroidectomy (partial resection,
PR) (P = .3; log-rank). b Patients
assigned to and receiving radio-
iodide treatment after TR of their
thyroid cancer (yes) fared better
than patients without radio-iodide
therapy (no) (P = .047; log-rank).
c DSS of patients treated with
external beam radiation (EBR)
after resection (yes) was worse
than their counterparts not
receiving EBR (no) (P \ .001;
log-rank) (c). Numbers below the
graphs show patients at risk at the
given time points
TABLE 4 Univariate analysis PTC and FTC for disease-specific survival after resection
Characteristics PTC FTC
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Age, \ 60 vs. [ 60 years 0.06 0.01–0.3 \.001* 0.2 0.1–0.42 \.001*
Tumor size, T1, 2 vs. [ T2 (\4 vs. C 4 cm) 0.15 0.03–0.79 .008* 0.85 0.33–2.17 .73
Radio-iodide therapy, yes vs. no 0.52 0.13–2.11 .28 0.39 0.19–0.80 .013*
EBR, yes vs. no 5.29 0.92–30.33 .001* 1.63 0.65–4.14 .23
Resection, PR vs. TR 1.22 0.38–3.91 .75 1.59 0.76–3.33 .24
PTC papillary thyroid carcinoma, FTC follicular thyroid carcinoma, EBR external beam radiation, PR partial thyroid resection, TR total or near-
total thyroid resection
HR was calculated with Cox-Mantel, P-values calculated with log-rank test
*Statistically significant differences between groups (P \ .05)
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1 g thyroid tissue left) thyroidectomy has the advantage that
synchronous tumors and tissue for metachronous disease is
removed (total thyroidectomy, 38%). Additional advantages
of total thyroidectomy is the increased efficiency of post-
operative RIA therapy and the decreased risk of damage to
the recurrent laryngeal nerve in case a second surgical
intervention is necessary as a result of recurrent disease.
Table 5 shows the DSS rate after partial thyroidectomy
and after total removal of the gland. For all patients, the
10- and 20-year DSS after partial thyroidectomy was 77
and 66%, respectively, and the 10- and 20-year DDS after
total thyroidectomy was 87 and 74%, respectively. The
Kaplan–Meier DSS estimates, stratified by histology and
the extent of resection, are shown in Fig. 4a–c; DSS after
PR and TR for PTC was 82 and 84%, respectively
(P = NS) (Fig. 4a); DSS rates for FTC were 47 and 63%
after PR and TR, respectively (P = NS) (Fig. 4b). No
statistically significant difference in DSS for the extent of
resection could be detected in patients with FTC, even
when the more aggressive Huertle cell carcinoma was
excluded (P = NS) (Fig. 4c). Hence, in this group of
selected patients who had complete removal of their
WDTC confined to the thyroid gland, with no macro-
scopically apparent lymph node invasion or distant
metastases, the extent of resection of the surrounding
thyroid tissue did not influence DSS. In this context, it is
important to note that lymphadenectomy was not routinely
performed, and if done at the surgeon’s discretion, was
limited to ipsilateral incomplete lymphadenectomy.
Postoperative complications were noted in 51 patients.
Postoperative transient recurrent paresis was detected
with postoperative laryngoscopy in 31 patients, and 1
patient required short-term tracheostomy due to bilateral
nerve paresis (10.6% with 292 nerves at risk); 17 of
these nerve lesions occurred in patients treated with PR
and 14 in patients with TR of the thyroid gland
(P = 0.42, Fisher exact test). Transient hypocalcaemia
was noted in 22 patients (13%) and occurred signifi-
cantly more often in patients who underwent total or
near-total thyroid resection (P = .001, Fisher exact). One
patient each had bleeding or infection, respectively, that
required intervention.
DISCUSSION
Findings
In this analysis of 166 patients with completely resected,
well-differentiated carcinoma that did not extend beyond
the thyroid capsule, and who were treated at a tertiary care
center over an 18-year period, the DSS of PTC and FTC
were 83 and 54%, respectively, during a median follow-up T
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of 27 years. The last death resulting from thyroid cancer
occurred 18 years after the initial resection. The estab-
lished prognostic factors for WDTC of age, gender,
histology, tumor size, and postoperative RIA therapy, were
significant factors for DSS in the univariate analysis. Age
was the dominant risk factor in a multivariate analysis.
Application of EBR after resection of the thyroid cancer
resulted in significantly decreased DSS. The extent of
thyroid resection, in addition to the complete removal of
the carcinoma, did not influence DSS.
Survival
Long-term follow-up studies from the United States and
Asia describe 20-year DSS rates for PTC without distant
metastasis of 92–96% (99%).7,36,37 These survival rates are
about 10% higher than in our population. This discrepancy
could be the result of etiologic differences that correlate
with geography, as reported 10-year and 20-year DSS from
Sweden, Germany, and Austria, where goiter is endemic or
prevented by iodide substitution, were similar or worse
compared with this study.3,9,38,39 Whereas tumor size
(median 50 mm) was slightly higher, the age distribution,
which was a major risk factor, was similar in our cohort
(median age, 41.3 years in the PTC group) with those
reported from countries without endemic goiter (United
States, Asia). Studies from regions with endemic goiter,
show that the proportion of FTC in patients with WDTC is
higher in these regions. Lerch et al. from Germany reported
40% FTC; Passler et al., 33%; and Steinmu¨ller et al.,
30%.39–41 In our population, FTC made up half of the
WDTC. However, the less favorable DSS in WDTC from
Europe could not be explained by the higher rate of FTCs
because the DSS for each histologic type was lower than in
analysis from outside Europe.
Considering the long-term risk of death from completely
resected WDTC confined to the thyroid gland found in this
study (17% for PTC and 46% for FTC), the axiom that this
disease displays a benign course might not be entirely
appropriate, and treatment nihilism is surely inadequate.
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FIG. 4 Kaplan–Meier curves for
disease-specific survival (DSS)
estimates stratified by extent of
resection in papillary thyroid
carcinoma (PTC) (a), follicular
thyroid carcinoma (FTC) (b), and
FTC excluding Huertle cell
carcinoma (c). a DSS in patients
with complete resection of PTC
was independent on the extent of
thyroid removal (TR: total thyroid
resection, PR: partial thyroid
resection) (P = .75). b DSS in
patients with complete resection
of follicular thyroid carcinoma
(FTC) was not significantly
different between TR and PR
(P = .37; log-rank) and remained
below significance levels when
patients with Huertle cell
carcinoma were excluded
(P = .65; log rank) (c)
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This is especially true for older patients, where the ten-
dency for ‘‘watchful waiting’’ in cases of newly detected
thyroid lesions is misguided. In our analysis, only a third of
patients older than 60 years of age did not die of their
disease. The fact that people grow to older ages and that the
incidence of WDTC peaks in the sixth decade adds further
weight to the importance of correct initial treatment.3
An important finding of this study is that no patients
died of their disease more than 18 years after complete
resection of the thyroid cancer. Although this is likely the
result of the very good prognosis for young patients and
the risk of death from cancer independent causes (com-
peting causes) in the older population, it is noteworthy.
Analyzing the Kaplan–Meier survival curves of other
long-term studies, it becomes evident that, indeed, death
resulting from WDTC is unlikely more than 15 years
after resection.3,7,36,37,39–41 This finding has direct impli-
cations for further studies evaluating risk factors and
prognostic parameters. Follow-up periods of 10 to
15 years are sufficient for a clinically significant evalua-
tion of WDTC.
Prognostic Parameters
Major prognostic factors for disease recurrence and
DSS in WDTC, namely patient age, gender, histology,
tumor size, presence of distant metastasis, extension
beyond the thyroid capsule, and completeness of resection
have been identified mostly based on large population-
based studies (cancer registries) with mid- to long-term
follow-ups. Because of the restrictions we used in our
attempt to limit our analysis to a more homogeneous
patient population, some of these factors could not be
evaluated (notably, lymph node metastasis). The findings
in this study confirm the reported prognostic parameters
in univariate analysis. ‘‘Age’’ was the all-dominant factor
for DSS followed by ‘‘histology’’ in the multivariate
analysis. However, the study likely lacked the power to
allow conclusive analysis of multiple parameters. Here we
also analyzed two controversial prognostic parameters;
extent of thyroid resection and postoperative application
of EBR.
Extent of Resection
The results presented here are from well-documented
interventions on primary tumors confined to the thyroid
gland, with no macroscopic spread to adjacent lymph
nodes. The surgical approach during the observation period
infrequently extended to regional lymph node sampling
(14%). This is why we decided not to take lymphadenec-
tomy into account, because lymphadenectomy similar to
current standards could not be verified. TR of the thyroid
tissue did not improve DSS compared with PR. Although
the Kaplan–Meier survival curves trended toward better
outcomes after TR, this effect was much less important
than other risk factors, namely, postoperative RIA therapy.
Most importantly, in patients with PTC, the WDTC variant
that is often multifocal and bilateral, there was no benefit
for TR, and the survival curves for TR and PR almost
overlap.
These results agree with most of the analysis from large
single-institution and SEER database mid-term studies that
favor hemithyroidectomy (lobectomy) of the affected side
over total thyroidectomy.14,19,20,24–29,31 Indeed, recom-
mendations and consensus guidelines advocating total or
near-total thyroidectomy in high-risk PTCs, but not nec-
essarily in single, small, low-risk, intrathyroidal lesions,
are not based on evidence demonstrating improved DSS,
but rather on an understanding of the disease being mul-
tifocal with an increased risk of recurrence and the option
to treat small residual thyroid cancer with RIA more
effectively.42,43 In addition, proponents of limited resection
base their strategy on publications reporting increased
postsurgical complications with more extensive resec-
tion.23 In the current analysis, we found an increased rate
of transient postoperative hypocalcemia in patients treated
with TR, but no difference in the rate of transient nerve
paralysis. Previous studies on TR at our institution could
not rectify limited resections based on nerve injury rates.44
However, guidelines recommending TR as the treatment of
choice also take into consideration that secondary total
thyroidectomy for disease recurrence has a higher risk of
complications than primary total thyroidectomy. Very
recently, Bilimoria et al. advocated TR in all PTC patients
with tumors greater than 1 cm based on a very large pop-
ulation from the National Cancer Data Base.45 However,
the limitations of this kind of study do not permit optimal
treatment recommendations or suggestions (see comments
by Shah).46 Most importantly, performance of lymphade-
nectomy was not taken into account in Bilimoria’s analysis
and could well explain the improved survival after com-
plete resection of the thyroid gland.
Generally, it must be assumed that retrospective analy-
ses of the extent of resection based on surgical reports
overestimate the rate of true total thyroidectomies. Schwab
et al. found residual thyroid tissue [1 mL in more than
one-third of patients reportedly treated with ‘‘total thy-
roidectomy’’ in postoperative scintigraphies (uptake
measures).38 The amount of thyroid tissue left behind
would not fulfill the criteria of ‘‘near-total thyroidectomy’’;
however, the volume of the remnant was below the limit
that could compromise RIA. We cannot exclude that this
reporting error could explain why there was no difference
in DSS after PR compared with total thyroidectomy.
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External Beam Radiation Therapy (EBR)
Our results show a negative effect of postoperative EBR
on DSS. This may be the result of patient selection, for
example, those with poor prognostic parameters who
required EBR, either combined with RIA or alone. How-
ever, age, histology, tumor size, surgery performed, and
completeness of resection of the 34 patients who received
EBR were similar to the group who did not receive EBR.
Because we included only patients who had complete
tumor resections, the negative effect of EBR in this select
group of patients with low to mid risk tumors is likely to be
real. However, one must consider the potentially subopti-
mal 30 Gy doses applied compared with the 60–70 Gy
used more recently.47,48 Lower doses were used historically
because older radiotherapy methods could not deliver an
adequate dose of radiation to the thyroid bed without
exceeding the tolerance of the posteriorly located spinal
cord. In 2003, Ford et al. reported that local recurrence and
OS are related to the dose prescribed, based on a small
cohort (n = 41), suggesting a dose of a least 50 Gy is
needed to impact local control and possibly survival.49 Our
findings concur with the recent management guidelines put
forth by the American Thyroid Association Guidelines
Taskforce, which considers EBR only for patients with
gross residual tumors and in whom further surgery or RIA
treatment are likely to be ineffective.42 According to the
relative radioresistance and slow regression rate of PTC,
Tuttle et al. reported no apparent advantage of EBR for OS,
but significant morbidities.50 Our findings strongly support
this notion for patients who have limited disease and
complete tumor resection.
Limitations of This Study
The most important limitation of this study is the small
number of patients included. The inherent risk that sig-
nificant differences could not be detected may be crucial in
assessing the influence of the extent of thyroid resection.
Indeed, with 166 patients included and a 20-year DSS rate
of 66% in patients with partially resected thyroid, the DSS
rate for TR would have to vary by [20% in order to
become statistically significant (we found an 8% difference
in DSS). However, the limited power of this study is partly
compensated for by the very long follow-up, which
allowed us to estimate trends in the Kaplan–Meier survival
curves. Whereas a certain divergence of the curves
depicting TR and PR in FTC over a 30-year time span was
observed, this was not true in the DSS curves of patients
with resected PTC. Here, the almost overlapping curves
would suggest that the nonsignificant difference between
TR and PR is real, and not merely the result of the study
being underpowered. Because most recognized prognostic
factors reach statistical significance despite the rather small
number of patients observed also suggests that the extent of
thyroid resection without lymphadenectomy is, at most, a
minor factor for DSS.
Accordingly, the effect of RIA after incomplete resec-
tion could not be estimated because of a lack of sufficient
power (only 37 patients did not receive RAI, and of these,
11 were treated with EBR). Moreover, of these 26 patients,
only 3 were treated with total thyroidectomy and none died
of thyroid cancer.
Another limitation is the exclusion of lymph node
metastases as prognostic factors. Unlike other studies, we
decided not to report or include nodal involvement because
lymphadenectomy during the period in question was het-
erogeneous and dependent on the individual physician’s
decision. The quality of lymphadenectomy cannot be
evaluated retrospectively. Adding lymph node metastases
to the survival analysis dating back more than 15 years
runs the risk of coming to the wrong conclusion. Scinti-
graphic uptake and pathologic analysis of retrospective
studies by Schwab et al. showed that 56% of lymph node
dissections did not fulfill the quality standards, even when
ipsilateral and centrocervical lymphadenectomy is reported
by the surgeon.38 Rather than use uncertain data, we pre-
ferred to exclude this factor from the analysis. Although
lymph node involvement is not an independent risk factor,
with the exclusion of lymphadenectomy, this study cannot
deny the possibility that complete thyroidectomy combined
with appropriate lymphadenectomy might improve DSS.
Strength of This Study
Studies with very long-term follow-up are often ham-
pered by inconsistencies in the applied treatment over time.
The major advantages of the study are the very-long fol-
low-up and the well-defined group of WDTC patients.
Unlike most other studies reporting 20-year survival rates,
this single-institutional database with detailed, prospec-
tively collected information was limited to a period during
which treatment standards and reporting remained the
same. It is likely that patients in single-institutional studies
reporting data over a 40-year period were treated differ-
ently, even when the surgical approaches were equally
termed. Technical improvements, exposure of the recurrent
laryngeal nerve, the definition of ‘‘subtotal,’’ ‘‘near total,’’
‘‘total thyroidectomy,’’ and most importantly, of complete
lymphadenectomy has changed over the last 4 decades.37
An analysis of these studies for independent factors runs
the risk of a time and treatment bias. In addition, large
observational studies based on population-based databases
suffer from a lack of detailed descriptions of the tumor
characteristics and treatment strategies. This is where the
strength and value of this study lies; in the long-term
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analysis of a small, very well defined group of WDTC
patients treated in a homogeneous manner.
Conclusions
Our findings agree with most of the literature reporting
on prognostic factors in WDTC. The unusually long follow-
up of a median 27 years showed that 18 years after a
complete resection, no more patients died of thyroid cancer,
but that disease-specific death rates of WDTC in Europe are
by no means negligible. Whereas EBR (at doses lower than
the present day standard) after complete resection of WDTC
confined to the thyroid negatively affected DSS, the effect
of extensive thyroid resection (without additional lym-
phadenectomy) compared with partial resection on DSS
was, at most, minimal (especially in PTC, where the sur-
vival curves overlapped). Future studies should focus on the
value of total or near-total thyroidectomy combined with
complete (ipsilateral and cervico-central) lymphadenec-
tomy compared with unilateral thyroidectomy with/without
ipsilateral lymphadenectomy. Our data, furthermore, sug-
gest that for future studies an observation period of 15 years
is probably sufficient. In addition, determination of any
molecular differences in PTC among Europeans, Asians,
and Americans could help explain the significant difference
in DSS of PTC reported by others and confirmed by our
findings.
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